HTG Molecular Diagnostics (HTGMQ)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Aug 15, 2024 09:31 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for HTG Molecular Diagnostics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 6 | 9 | 9 | 19 |
Cost Of Goods | NA | 5 | 4 | 4 | 9 |
Gross Profit | NA | 2 | 5 | 5 | 10 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 23 | 23 | 24 | 29 |
Income After Depreciation & Amortization | 0 | -21 | -18 | -20 | -19 |
Non-Operating Income | NA | 0 | 2 | 0 | 1 |
Interest Expense | NA | 1 | 1 | 1 | 1 |
Pretax Income | NA | -22 | -17 | -21 | -19 |
Income Taxes | NA | -22 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | 0 | -17 | -21 | -19 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -22 | -17 | -21 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -20 | -17 | -18 | -17 |
Depreciation & Amortization (Cash Flow) | NA | 1 | 1 | 2 | 2 |
Income After Depreciation & Amortization | 0 | -21 | -18 | -20 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | NA | 0.58 | 0.39 | 0.21 |
Diluted EPS Before Non-Recurring Items | NA | NA | -32.17 | -53.06 | -91.79 |
Diluted Net EPS (GAAP) | NA | -24.28 | -29.65 | -54.14 | -91.79 |
Fiscal Year end for HTG Molecular Diagnostics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |